PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Curr Pharm Des. Author manuscript; available in PMC 2010 July 1.
Published in final edited form as:
PMCID: PMC2895311
NIHMSID: NIHMS208469

The Role of the Cell Surface LRP and Soluble LRP in Blood-Brain Barrier Aβ Clearance in Alzheimer’s Disease

Abstract

Low-density lipoprotein receptor related protein-1 (LRP) is a member of the low-density lipoprotein (LDL) receptor family which has been linked to Alzheimer’s disease (AD) by biochemical and genetic evidence. Levels of neurotoxic amyloid -peptide (Aβ) in the brain are elevated in AD contributing to the disease process and neuropathology. Faulty A clearance from the brain appears to mediate focal Aβ accumulations in AD. Central and peripheral production of Aβ from Aβ-precursor protein (APP), transport of peripheral Aβ into the brain across the blood-brain barrier (BBB) via receptor for advanced glycation end products (RAGE), enzymatic Aβ degradation, Aβ oligomerization and aggregation, neuroinflammatory changes and microglia activation, and Aβ elimination from brain across the BBB by cell surface LRP; all may control brain Aβ levels. Recently, we have shown that a soluble form of LRP (sLRP) binds 70 to 90 % of plasma Aβ, preventing its access to the brain. In AD individuals, the levels of LRP at the BBB are reduced, as are levels of Aβ binding to sLRP in plasma. This, in turn, may increase Aβ brain levels through a decreased efflux of brain Aβ at the BBB and/or reduced sequestration of plasma Aβ associated with re-entry of free Aβ into the brain via RAGE. Thus, therapies which increase LRP expression at the BBB and/or enhance the peripheral Aβ “sink” activity of sLRP, hold potential to control brain Aβ accumulations, neuroinflammation and cerebral blood flow reductions in AD.

Keywords: LRP, sLRP, blood-brain barrier, Alzheimer’s disease, Aβ clearance

INTRODUCTION

Transport of polar solutes across the cerebrovascular endothelial cells is restricted by the presence of tight junctions, which form the blood-brain barrier (BBB) [1, 2]. Amyloid -peptides (Aβ) are small peptides (~ 4.5 kDa) of which the most common isoforms contain 40 (Aβ40) or 42 (Aβ42) amino acids. A circulates in plasma, cerebrospinal fluid (CSF) and brain interstitial fluid (ISF) mainly bound to its chaperone molecules [2]. A smaller fraction of Aβ in these body fluids remains unbound and circulates as free Aβ in equilibrium with bound Aβ. In human plasma, a soluble form of the low-density lipoprotein receptor related protein-1 (LRP), sLRP, is a major binding protein for circulating Aβ [3]. In human CSF, lipocalin-type prostaglandin D synthase/ -trace appears to be a major Aβ chaperone [4]. In addition, apolipoprotein J (apoJ), apoE, transthyretin and α2-macroglobulin (α2M) bind Aβ in the CSF and ISF, and may influence its clearance, metabolism and aggregation [59]. In normal human CSF and plasma, Aβ 40 levels are greater than those of Aβ 42 by about 10-fold and 1.5-fold, respectively [10].

Aβ concentration in normal brain ISF is regulated by its rate of production from the Aβ-precursor protein (APP), influx or re-entry into the brain mainly via receptor for advanced glycation end products (RAGE) [11] and by Aβ clearance at the BBB [1213] (Fig. 1) and within the brain itself [14]. APP, a type I transmembrane protein, is expressed in almost all cell types in the body and in the brain, including brain endothelial cells, astrocytes and neurons [2, 15]. APP proteolysis is mediated by two major pathways; a nonamyloidogenic pathway involving α-and γ-secretase, and amyloidogenic pathway involving β-and γ-secretase [15]. Clearance of Aβ from brain ISF involves non-enzymatic transport mechanisms and enzymatic degradation. There are two pathways for the nonenzymatic Aβ clearance. The major one is transcytosis across the BBB (BBB clearance) which is mediated mainly by the cell surface LRP localized predominantly on the abluminal side of the cerebral endothelium [16, 17]. The second pathway involves bulk flow of the ISF into the CSF followed by drainage into the blood across the perivascular Virchow-Robin arterial spaces which under physiological conditions accounts for about 10–15% of total Aβ clearance in mice [16, 18]. The enzymatic clearance involves a number of proteases, including insulin-degrading enzyme, neprilysin and endothelin-converting enzyme (cellular clearance) [1921]. Importantly, degradation of free A in brain ISF appears to be insignificant [16].

Fig. 1
Schematic diagram showing the blood and brain compartments, and the roles of the cell surface LRP and soluble LRP (sLRP) in the regulation of Aβ transport across the blood-brain barrier (BBB). See text for details. RAGE (receptor for advanced ...

Circulating Aβ can enter into the brain in guinea pigs, mice, monkeys and rats across the BBB by a saturable specialized transport mechanism in addition to diffusional transport [11, 2228]. In guinea-pigs, Aβ 40 permeability across the BBB is greater than that of immunoglobulin G (IgG) [29], arginine-vasopressin [30] and leucine-enkephalin [31, 32] by 11-fold, 2.5-fold and 1.5-fold, respectively (Table 1), but is lower by about 5-fold than transport of amino acid tyrosine across either the BBB or the choroid plexus [33, 34]. In AD models, expression of RAGE, which mediates Aβ influx across the BBB, is increased [11, 35]. Similarly, in AD individuals, expression of RAGE in brain endothelial vascular cells is increased [11, 36, 37], whereas that of LRP is reduced [16, 17, 37] which, together, favor Aβ accumulation in brain. Increased RAGE vascular expression may also mediate Aβ-induced migration of monocytes across the human brain endothelial cells [38]. Interestingly, exercise reduces RAGE expression at the BBB and Aβ influx, and increases LRP BBB expression and Aβ efflux in an animal model of AD [39]. Aβ accumulation in brain leads to its gradual oligomerization and greater levels of neurotoxic Aβ oligomer species [4042]. Thus, continuous removal of Aβ from the CNS is the most important mechanism for preventing potentially neurotoxic accumulations of Aβ in brain [43].

Table 1
Blood-Brain Barrier Permeability for A 40, Leucine-Enkephalin, Arginine-Vasopressin and IgG Expressed as Unidirectional Transfer Constant (Kin) in Guinea-Pigs

LRP

LRP is a large multifunctional scavenger and signaling receptor and a member of the LDL receptor family [44, 45]. It plays a major role in the transport and metabolism of cholesterol associated with apoE-containing lipoproteins. LRP is synthesized as a single polypeptide precursor (600 kDa) that is processed into two heterodimeric peptides, the and chains, by furin in the trans-Golgi network [46]. The heavy -chain of LRP (515 kDa) forms the extracellular domain and is non-covalently coupled to the 85 kDa transmembrane and cytoplasmic light -chain. The -chain contains four ligand-binding domains (clusters I-IV), consisting of 2, 8, 10, and 11 cysteine-rich complement-type repeats, respectively [47]. Between these clusters there are epidermal growth factor (EGF) receptor-like repeats and YWTD -propeller repeats that are typical of the LDL receptor family [47]. LRP binds a diverse array (~40) of structurally and functionally unrelated ligands, such as apoE, α2M, tissue plasminogen activator (tPA), proteinase-inhibitors (plasminogen activator inhibitor-1), APP, blood coagulation factors (e.g., factor VIII, protein S), growth factors, bacteria and viral proteins, lactoferrin [45] and Aβ wild type and mutant peptides [17]. Although LRP is mainly an endocytic receptor, it has been shown that LRP mediates transcytosis of both Aβ [16, 17] and tPA [48] across the BBB. The majority of ligands bind to clusters II and IV [44, 49]. RAP (receptor-associated protein), an endoplasmic reticulum (ER) molecular chaperone for the LDL receptor family, binds LRP with high affinity, and not only prevents premature ligand binding to LRP but is also required for proper LRP folding [50].

The light chain of LRP (85 kDa) contains the transmembrane domain and a cytoplasmic tail which contains both tyrosine and serine phosphorylation sites [51]. Phosphorylation of LRP in response to nerve growth factor accelerates the endocytic activity of the receptor [52], whereas phosphorylation by platelet-derived growth factor does not have a clear effect on endocytosis [53]. The cytoplasmic tail contains two NPXY and one YXXL motifs and two di-leucine motifs [54]. The YXXL motif and distal di-leucine repeat have been shown to be the main feature required for rapid LRP endocytosis or internalization (< 0.5 s) [55]. This rapid endocytotic rate of LRP indicates its major role as a cargo transporter. In addition, the cytoplasmic domain interacts with a number of adaptor proteins, such as disabled-1, FE65 and PSD-95, suggesting a signal transduction role of LRP [56, 57]. Thus, LRP has a dual role as a rapid cargo transporter and the transmembrane cell signaling receptor.

LRP AND ALZHEIMER’S DISEASE

LRP has been linked to AD by genetic and biochemical studies. Polymorphisms in the LRP gene on chromosome 12 in a 5′ tetranucleotide repeat and a single base pair change within exon 3 (C766T) may be associated with late-onset AD [5860] and cerebral amyloid angiopathy [61], but this has not been confirmed by all studies [62]. The C to T change in exon 3 has been identified in some ethnic groups [59, 63]. LRP and its ligands have been detected in senile plaques [64, 65]. LRP interacts with APP in neurons and may influence APP processing and metabolism, and thereby production of Aβ, the neurotoxic species central to the pathogenesis of AD [66, 67]. LRP expressed in neurons may regulate Aβ uptake (cellular uptake within brain) via LRP ligands α2M and apoE [6871]. However, LRP expression on neurons does not appear to mediate Aβ clearance in vivo since APP mice overexpressing functional LRP mini-receptors on neurons have increased levels of soluble Aβ in brain [72, 73]. LRP is expressed in brain capillary endothelium [16, 17]. Its reduced brain capillary expression has been observed during normal aging in rodents, non-human primates and in AD patients associated with positive staining of cerebral vessels for Aβ40 and Aβ42 [16, 17, 37, 39]. Since LRP is the main receptor for Aβ transport across the BBB from brain to blood, its down regulation in brain endothelium in AD individuals and patients with Dutch-type cerebrovascular β-amyloidosis likely reduces Aβ clearance and promotes Aβ cerebrovasccular and brain focal accumulations. In an AD mouse model (TgCRND8), exposure to enriched environment for 120 days beginning at 30 days of age promoted upregulation of LRP associated with reductions in Aβ levels [39]. This demonstrates that LRP expression can be regulated by environmental and behavioral factors.

LRP AND BBB Aβ CLEARANCE

In a recent study, human Aβ microinjected into the mouse brain was detected in plasma using human specific ELISA for intact Aβ [8]. This clearly demonstrates intact Aβ transcytosis from brain ISF into blood. Aβ clearance may be influenced by apoE and α2M, known ligands for LRP, but formation of Aβ complexes with either of those ligands has not been shown in the CNS in vivo during clearance studies [16, 17]. Direct LRP/Aβ interaction in vitro has been demonstrated by surface plasmon resonance (SPR) analysis and ELISA assays, as well as the direct binding of Aβ to the abluminal side of brain capillaries, which suggests that this interaction is the first step of Aβ transcytosis across the mouse BBB in vivo [8,17]. The affinity of Aβ40 for LRP is greater than that of Aβ42 and the vasculotropic mutants, e.g., Dutch/Iowa (DI) Aβ40. Compared to Aβ40, the Aβ peptides with higher β-sheet content and/or more negative charges (Aβ42 and DI Aβ40) are cleared less efficiently from brain. Despite extremely low levels of human APP in brain and low Aβ production from neurons, the transgenic TgDI/Swe mice (Dutch, Iowa and Swedish mutations, Thy-1 APP DI/Swe mice) develop robust Aβ brain accumulation much earlier than Tg2576 Aβ-overproducing mice [17,74]. The mutant Dutch Aβ, E22Q, is also cleared less efficiently from brain to blood [75]. This clearly demonstrates that genetic mutations resulting in errors in Aβ clearance significantly contribute to Aβ accumulation in brain. Other lipoprotein receptors, such as LDLR, VLDLR, LRP2, appear to have no major role in transport of free Aβ across the BBB into blood [17], but their roles in transporting Aβ bound to its chaperone proteins apoE and apoJ remain to be elucidated. LRP2/megalin is typically expressed on the apical membrane of epithelial cells [76]. It has been shown to transport RAP, an endoplasmic reticulum chaperone molecule for the LDL receptor family, in vitro across polarized epithelial cells from the apical to the basolateral chamber, and in vivo into the brain in mice [77]. In addition, LRP2/megalin transports apoJ and Aβ/apoJ complexes from blood to brain [78]. However, this transport process is completely saturated at physiological levels of plasma apoJ, and therefore unlikely to play a key role in the regulation of Aβ levels in brain ISF. A recent study using an in vitro kidney epithelial monolayer as a transport model has shown that cells transfected with LRP minireceptor containing cluster IV of LRP (mLRP4) mediate Aβ endocytosis followed by its degradation [79]. This study revealed no role for P glycoprotein (Pgp) in Aβ transport, which had been previously reported to influence Aβ brain levels in vivo [80]. Although epithelial transport models mimic most physicochemical properties of endothelial monolayer, genomic and proteomic studies suggest a unique molecular makeup of brain endothelial monolayers [81], which differ from both systemic endothelial cells and epithelial cells. This might account, in part, for the lack of measurable transcytosis of LRP ligands in epithelial kidney monolayers [79], whereas, in brain endothelial monolayers, LRP-mediated transcytosis of tPA across a bovine BBB model has been reported [48]. Also, in contrast to typical in vivo and in vitro BBB studies demonstrating relatively rapid clearance of Aβ [8, 16, 17, 80] [48], the Aβ uptake across the kidney epithelial monolayer required much longer equilibration time (up to 48 h) [79] which might account for the observed differences compared to LRP-mediated transcytosis demonstrated across brain endothelial monolayers [48].

LRP AND SYSTEMIC Aβ CLEARANCE

sLRP is the truncated extracellular domain of LRP which is normally present in plasma [82]. sLRP is released into the extracellular fluid after beta-secretase cleavage of the LRP β-chain [83]. Our recent data show that endogenous native sLRP is a major peripheral Aβ binding protein in humans and mice [3]. In humans, sLRP normally sequesters ~70–90% of circulating Aβ. However, in AD we showed decreased binding of Aβ to sLRP due to lower sLRP levels. In addition, we detected increased oxidation of sLRP, which was associated with a 3-4-fold increase in free Aβ40 and Aβ42 levels in plasma. These findings suggest that the endogenous sLRP “peripheral sink” for Aβ is compromised in AD, leading to an elevated free Aβ fraction in plasma that may contribute to increased Aβ levels in the brain via RAGE-mediated transport [11, 37].

Continuous systemic Aβ clearance and sLRP sequestration of plasma Aβ are essential components of peripheral Aβ “sink” action which regulates Aβ removal from brain. In turn, liver LRP mediates systemic elimination of Aβ from plasma [84]. We also showed that recombinant LRP clusters could effectively sequester plasma Aβ (both 40 and 42) in human AD plasma and in AD mice. In the mice, this sequestration resulted in reductions of Aβ parenchymal and vascular accumulations and amyloid load, as well as improvements in memory, learning and CBF responses [3]. Curiously, sLRP is also protective against peripheral nerve injury and neuropathic pain in mice [85]. Other Aβ-binding agents, such as anti-Aβ antibody [86,87], can also promote clearance of brain-derived Aβ in APP overexpressing mice, but are not endogenous Aβ sink agents and therefore are often associated with unwanted side effects. Since oxidation of LRP is associated with aging [3], antioxidants with angiogenic and vasculoprotective properties under hypoxic conditions, such as activated protein C [88], might prove beneficial against Aβ-induced oxidant stress associated with LRP oxidation.

CONCLUSION

LRP in brain capillaries plays a key role in Aβ elimination from the brain by mediating its clearance across the BBB. In plasma, a soluble form of LRP, sLRP, maintains a native Aβ peripheral ‘sink’ activity, which is critical for efficient Aβ efflux from the brain. In AD, both LRP levels at the BBB and peripheral sLRP binding of Aβ are compromised, favoring Aβ accumulation in the brain. Thus, therapies focused on upregulation of the cell surface LRP in brain endothelial cells and on replacement of sLRP in plasma, as, for example, with recombinant high affinity Aβ binding LRP clusters, represent promising new mechanisms to therapeutically control Aβ levels in brain.

Acknowledgments

We thank Dr. Eleanor Carson-Walter for editing the manuscript and Margaret Parisi for preparing the illustration. This study was supported by R37AG023084 and R37NS34467 to BVZ and NS50427 to RD.

References

1. Begley DJ, Brightman M. Structural and functional aspects of the blood-brain barrier. Prog Drug Res. 2003;61:39–78. [PubMed]
2. Zlokovic B. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57:178–201. [PubMed]
3. Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, et al. Clearance of amyloid-β by circulating lipoprotein receptors. Nat Med. 2007;13:1029–31. [PMC free article] [PubMed]
4. Kanekiyo T, Ban T, Aritake K, Huang ZL, Qu WM, Okazaki I, et al. Lipocalin-type prostaglandin D synthase/beta-trace is a major amyloid beta-chaperone in human cerebrospinal fluid. Proc Natl Acad Sci USA. 2007;104:6412–7. [PubMed]
5. Holtzman DM, Zlokovic BV. Role of Aβ transport and clearance in the pathogenesis and treatment of Alzheimer’s disease. In: Sisodia S, Tanzi R, editors. Alzheimer’s disease: advances in genetics, molecular and cellular biology. Springer; 2007. pp. 179–98.
6. Ghiso J, Frangione B. Amyloidosis in Alzheimer’s disease. Adv Drug Deliv Rev. 2002;54:1539–53. [PubMed]
7. Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zheng G, McCluskey RT, et al. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci USA. 1996;93:4229–34. [PubMed]
8. Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, et al. Transport pathways for clearance of human Alzheimer’s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab. 2007;27:909–18. [PMC free article] [PubMed]
9. Martel CL, Mackic JB, Matsubara E, Governale S, Miguel C, Miao W, et al. Isoform-specific effects of apolipoproteins E2, E3, E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer’s amyloid β J Neurochem. 1997;69:1995–2004. [PubMed]
10. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512–9. [PubMed]
11. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med. 2003;9:907–13. [PubMed]
12. Deane R, Wu Z, Zlokovic BV. RAGE (YIN) versus LRP (YANG) balance regulates Alzheimer amyloid β-peptide clearance through transport across the blood-brain barrier. Stroke. 2004;35:2628–31. [PubMed]
13. Deane R, Zlokovic BV. Role of the blood-brain barrier in the pathogenesis of Alzheimer’s disease. Curr Alzheimer Res. 2007;4:191–7. [PubMed]
14. Selkoe DJ. Clearing the brain’s amyloid cobwebs. Neuron. 2001;32:177–80. [PubMed]
15. Selkoe DJ. Alzheimer’s disease: genotypes, phenotypes, and treatments. Science. 1997;275:630–31. [PubMed]
16. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, et al. Clearance of Alzheimer’s amyloid-β1 - 40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest. 2000;106:1489–99. [PMC free article] [PubMed]
17. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Aβ isoforms. Neuron. 2004;43:333–44. [PubMed]
18. Silverberg GD, Mayo M, Saul T, Rubenstein E, McGuire D. Alzheimer’s disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol. 2003;2:506–11. [PubMed]
19. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, et al. Identification of the major Abeta1–42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med. 2000;6:143–150. [PubMed]
20. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, et al. Metabolic regulation of brain Abeta by neprilysin. Science. 2001;292:1550–2. [PubMed]
21. Farris W, Leissring MA, Hemming ML, Chang AY, Selkoe DJ. Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein. Biochemistry. 2005;44:6513–25. [PubMed]
22. Zlokovic BV, Ghiso J, Mackic JB, McComb JG, Weiss MH, Frangione B. Blood-brain barrier transport of circulating Alzheimer’s amyloid-β Biochem Biophys Res Comm. 1993;197:1034–40. [PubMed]
23. Maness LM, Banks WA, Podlisny MB, Selkoe DJ, Kastin AJ. Passage of human amyloid-β protein 1–40 across the murine bloodbrain barrier. Life Sci. 1994;55:1643–50. [PubMed]
24. Clifford PM, Zarrabi S, Sin G, Kinsler KJ, Kosciuk MC, Venkatarman V, et al. Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons. Brain Res. 2007;1142:223–36. [PubMed]
25. Martel CL, Mackic JB, McComb JG, Ghiso J, Zlokovic BV. Blood-brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer’s amyloid-β in guinea pigs. Neurosci Lett. 1996;206:157–60. [PubMed]
26. Mackic JB, Weiss MH, Miao W, Kirkman E, Ghiso J, Calero M, et al. Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer’s amyloid β peptide in aged squirrel monkey with cerebral amyloid angiopathy. J Neurochem. 1998;70:210–15. [PubMed]
27. Mackic JB, Stins M, McComb JG, Calero M, Ghiso J, Kim KS, et al. Human blood-brain barrier receptors for Alzheimer’s amyloid-β J Clin Invest. 1998;102:734–43. [PMC free article] [PubMed]
28. Mackic JB, Bading J, Ghiso J, Walker L, Wisniewski T, Frangione B, et al. Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer’s disease lesions. Vascul Pharmacol. 2002;38:303–13. [PubMed]
29. Zlokovic BV, Skundric DS, Segal MB, Lipovac MN, Davson H. A saturable mechanism for transport of immunoglobulin G across the blood-brain barrier of the guinea-pig. Exp Neurol. 1990;107:263–70. [PubMed]
30. Zlokovic BV, Banks WA, El Kadi H, Erchegyi J, Mackic JB, McComb JG, et al. Transport, uptake, and metabolism of bloodborne vasopressin by the blood-brain barrier. Brain Res. 1992;590:213–18. [PubMed]
31. Zlokovic BV, Begley DJ, Chain-Eliash DG. Blood-brain barrier permeability to leucine-enkephalin, D-alanine2-D-leucine5-enkephalin and their N-terminal amino acid (tyrosine) Brain Res. 1985;336:125–32. [PubMed]
32. Zlokovic BV, Mackic JB, Djuricic B, Davson H. Kinetic analysis of leucine-enkephalin cellular uptake at the luminal side of the blood-brain barrier of an in situ perfused guinea-pig brain. J Neurochem. 1989;53:1333–40. [PubMed]
33. Zlokovic BV, Begley DJ, Chain-Eliash DG. Blood-brain barrier permeability to leucine-enkephalin, D-alanine2-D-leucine5-enkephalin and their N-terminal amino acid (tyrosine) Brain Res. 1985;336:125–32. [PubMed]
34. Segal MB, Preston JE, Collis CS, Zlokovic BV. Kinetics and Na independence of amino acid uptake by blood side of perfused sheep choroid plexus. Am J Physiol. 1990;258:F1288–94. [PubMed]
35. LaRue B, Hogg E, Sagare A, Jovanovic S, Maness L, Maurer C, et al. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer’s Tg2576 mice. J Neurosci Meth. 2004;138:233–42. [PubMed]
36. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. Nature. 1996;382:685–91. [PubMed]
37. Donahue JE, Flaherty SL, Johanson CE, Duncan JA, 3rd, Silverberg GD, Miller MC, et al. RAGE, LRP1, and amyloid-beta protein in Alzheimer’s disease. Acta Neuropathol. 2006;112:405–15. [PubMed]
38. Giri R, Shen Y, Stins M, Du Yan S, Schmidt AM, Stern D, et al. beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. Am J Physiol Cell Physiol. 2000;279:C1772–81. [PubMed]
39. Herring A, Yasin H, Ambrée O, Sachser N, Paulus W, Keyvani K. Environmental enrichment counteracts Alzheimer’s neurovascular dysfunction in TgCRND8 mice. Brain Pathol. 2008;18:32–9. [PubMed]
40. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486–9. [PubMed]
41. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101–12. [PubMed]
42. Hardy J. Amyloid double trouble. Nat Med. 2006;38:11–2. [PubMed]
43. Zlokovic BV, Yamada S, Holtzman D, Ghiso J, Frangione B. Clearance of amyloid-β peptide from brain: transport or metabolism? Nature Med. 2000;6:718–9. [PubMed]
44. Herz J. The LDL receptor gene family: (un)expected signal transducers in the brain. Neuron. 2001;29:571–81. [PubMed]
45. Herz J, Strickland DK. LRP: a multifunctional scavenger and signaling receptor. J Clin Invest. 2001;108:779–84. [PMC free article] [PubMed]
46. Willnow TE, Rohlmann A, Horton J, Otani H, Braun JR, Hammer RE, et al. RAP, a specialized chaperone, prevents ligand-induced ER retention and degradation of LDL receptor-related endocytic receptors. EMBO J. 1996;15:2632–9. [PubMed]
47. Meijer AB, Rohlena J, van der Zwaan C, van Zonneveld AJ, Boertjes RC, Lenting PJ, et al. Functional duplication of ligandbinding domains within low-density lipoprotein receptor-related protein for interaction with receptor associated protein, alpha2-macroglobulin, factor IXa and factor VIII. Biochim Biophys Acta. 2007;774:714–22. [PubMed]
48. Benchenane K, Berezowski V, Fernnandez-Monreal M, Brillault J, Valable S, Dehouch M-P, et al. Oxygen glucose deprevation switch the transport of tPA across the blood brain barrier from an LRPdependent to an increased LRP-independent process. Stroke. 2005;36:1059–1064. [PubMed]
49. Obermoeller-McCormick LM, Li Y, Osaka H, FitzGerald DJ, Schwartz AL, Bu G. Dissection of receptor folding and ligandbinding property with functional minireceptors of LDL receptorrelated protein. J Cell Sci. 2001;114:899–908. [PubMed]
50. Bu G. The roles of receptor-associated protein (RAP) as a molecular chaperone for members of the LDL receptor family. Int Rev Cytol. 2001;209:76–116. [PubMed]
51. Van der Geer P. Phosphorylation of LRP1: regulation of transport and signal transduction. Trends Cardiovasc Med. 2002;12:160–5. [PubMed]
52. Bu G, Sun Y, Schwartz AL, Holtzman DM. Nerve growth factor induces rapid increases in functional cell surface low density lipoprotein receptor-related protein. J Biol Chem. 1998;273:13359–65. [PubMed]
53. Green PS, Bu G. Genetics and molecular biology: phosphorylation of low density lipoprotein receptor-related protein by plateletderived growth factor. Curr Opin Lipidol. 2002;13:569–72. [PubMed]
54. Li Y, Marzolo MP, van Kerkhof P, Strous GJ, Bu G. The YXXL motif, but not the two NPXY motifs, serves as the dominant endo blood-brain barrier of an in situ perfused guinea-pig brain. J Neurochem. 1989;53:1333–40. [PubMed]
55. Li Y, Lu W, Marzolo MP, Bu G. Differential functions of members of the low density lipoprotein receptor family suggested by their distinct endocytosis rates. J Biol Chem. 2001;276:18000–6. [PubMed]
56. Trommsdorff M, Borg JP, Margolis B, Herz J. Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein. J Biol Chem. 1998;273:33556–60. [PubMed]
57. Gotthardt M, Trommsdorff M, Nevitt MF, Shelton J, Richardson JA, Stockinger W, et al. Interactions of the low density lipoprotein receptor gene family with cytosolic adaptor and scaffold proteins suggest diverse biological functions in cellular communication and signal transduction. J Biol Chem. 2000;275:25616–24. [PubMed]
58. Kang DE, Saitoh T, Chen X, Xia Y, Masliah E, Hansen LA, et al. Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer’s disease. Neurology. 1997;49:56–61. [PubMed]
59. Lambert JC, Wavrant-DeVriéze F, Amouyel P, Chartier-Harlin MC. Association at LRP gene locus with sporadic late-onset Alzheimer’s disease. Lancet. 1998;351:1787–88. [PubMed]
60. Wavrant-DeVrieze F, Lambert JC, Stas L, Crook R, Cottel D, Pasquier F, et al. Association between coding variability in the LRP gene and the risk of late-onset Alzheimer’s disease. Hum Genet. 1999;104:432–34. [PubMed]
61. Christoforidis M, Schober R, Krohn K. Genetic-morphologic association study: association between the low density lipoproteinreceptor related protein (LRP) and cerebral amyloid angiopathy. Neuropath Appl Neurobiol. 2005;31:11–19. [PubMed]
62. Bertram L, Blacker D, Crystal A, Mullin K, Keeney D, Jones J, et al. Candidate genes showing no evidence for association or linkage with Alzheimer’s disease using family-based methodologies. Exp Gerontol. 2000;35:1353–61. [PubMed]
63. Baum L, Chen L, Ng HK, Chan YS, Mak YT, Woo J, et al. Low density lipoprotein receptor related protein gene exon 3 polymorphism association with Alzheimer’s disease in Chinese. Neurosci Lett. 1998;247:33–6. [PubMed]
64. Rebeck GW, Harr SD, Strickland DK, Hyman BT. Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the alpha 2-macroglobulin receptor/low-densitylipoprotein receptor-related protein. Ann Neurol. 1995;37:211–17. [PubMed]
65. Arélin K, Kinoshita A, Whelan CM, Irizarry MC, Rebeck GW, Strickland DK, et al. LRP and senile plaques in Alzheimer’s disease: colocalization with apolipoprotein E and with activated astrocytes. Brain Res Mol Brain Res. 2002;104:38–46. [PubMed]
66. Cam JA, Bu G. Modulation of beta-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family. Mol Neurodegener. 2006;1:8. [PMC free article] [PubMed]
67. Moir RD, Tanzi RE. LRP-mediated clearance of Abeta is inhibited by KPI-containing isoform of APP. Curr Alzheimer Res. 2005;2:269–73. [PubMed]
68. Narita M, Holtzman DM, Schwartz AL, Bu G. Alpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J Neurochem. 1997;69:1904–11. [PubMed]
69. Qiu Z, Strickland DK, Hyman BT, Rebeck GW. Alpha2-macroglobulin enhances the clearance of endogenous soluble betaamyloid peptide via low-density lipoprotein receptor-related protein in cortical neurons. J Neurochem. 1999;73:1393–8. [PubMed]
70. Bu G, Cam J, Zerbinatti C. LRP in amyloid-beta production and metabolism. Ann NY Acad Sci. 2006;1086:35–53. [PubMed]
71. DeMattos RB, Cirrito JR, Parsadanian M, May PC, O’Dell MA, Taylor JW, et al. ApoE and clusterin cooperatively suppress Aβ levels and deposition: evidence that apoE regulates extracellular Aβ metabolism in vivo. Neuron. 2004;41:193–202. [PubMed]
72. Zerbinatti CV, Bu G. LRP and Alzheimer’s disease. Rev Neurosci. 2005;6:123–35. [PubMed]
73. Zerbinatti CV, Wozniak DF, Cirrito J, Cam JA, Osaka H, Bales KR, et al. Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. Proc Natl Acad Sci USA. 2004;101:1075–80. [PubMed]
74. Davis J, Xu F, Deane R, Romanov G, Previti ML, Zeigler K, et al. Early-onset and robust cerebral microvascular accumulation of amyloid β-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid β-protein precursor. J Biol Chem. 2004;279:20296–306. [PubMed]
75. Monro OR, Mackic JB, Yamada S, Segal MB, Ghiso J, Maurer C, et al. Substitution at codon 22 reduces clearance of Alzheimer’s amyloid-beta peptide from the cerebrospinal fluid and prevents its transport from the central nervous system. Neurobiol Aging. 2002;23:405–412. [PubMed]
76. Marzolo M-P, Yuseff MI, Retamal C, Donoso M, Ezquer F, Farfan P, Li Y, Bu G. Differential distribution of low-density lipoproteinreceptor-related protein (LRP) and megalin in polarizad epithelial cells is determined by their cytoplasmic domains. Traffic. 2003;4:273–288. [PubMed]
77. Pa W, Kastin AJ, Zankel TC, van Kerkhof P, Terasaki T, Bu G. Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier. J cell Sci. 2004;117:5071–5078. [PubMed]
78. Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zheng G, mcCluskey RT, et al. Glycoprotein 330/megalin: probable rloe in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer’s disease amyloid β at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci USA. 1996;93:4229–4234. [PubMed]
79. Nazer B, Hong S, Selkoe DJ. LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-beta peptide in a blood-brain barrier in vitro model. Neurobiol Dis. 2008;30:94–102. [PMC free article] [PubMed]
80. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest. 2005;115:3285–90. [PMC free article] [PubMed]
81. Wu Z, Guo H, Chow N, Sallstrom J, Bell RD, Deane R, et al. Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat Med. 2005;11:959–65. [PubMed]
82. Quinn KA, Grimsley PG, Dai YP, Tapner M, Chesterman CN, Owensby DA. Soluble low density lipoprotein receptor-related protein (LRP) circulates in human plasma. J Biol Chem. 1997;272:23946–51. [PubMed]
83. Von Arnim CA, Kinoshita A, Peltan ID, Tangredi MM, Herl L, Lee BM, et al. The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J Biol Chem. 2005;280:17777–85. [PubMed]
84. Tamaki C, Ohtsuki S, Iwatsubo T, Hashimoto T, Yamada K, Yabuki C, et al. Major involvement of low-density lipoprotein receptor-related protein-1 in the clearance of plasma free amyloid beta-peptide by the liver. Pharm Res. 2006;23:1407–16. [PubMed]
85. Gaultier A, Arandjelovic S, Li X, Janes J, Dragojlovic N, Zhou GP, et al. A shed form of LDL receptor-related protein-1 regulates peripheral nerve injury and neuropathic pain in rodents. J Clin Invest. 2008;118:161–72. [PMC free article] [PubMed]
86. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer’s disease. Science. 2002;295:2264–67. [PubMed]
87. Deane R, Sagare A, Hamm K, Parisi M, LaRue B, Guo H, et al. IgG-assisted age-dependent clearance of Alzheimer’s amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci. 2005;25:11495–503. [PubMed]
88. Griffin JH, Zlokovic BV, Fernandez JA. Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke. Semin Hematol. 2002;39:197–205. [PubMed]